John de Kruif

Chief Tech/Sci/R&D Officer at MERUS N.V.

60 year

Health Technology

Consumer Services

Profile

John de Kruif is currently the Chief Technology Officer & Senior Vice President at Merus NV since 2013.
Prior to his current position, he worked as the Director-Antibody Discovery at Crucell NV from 2000 to 2006.
Dr. de Kruif holds a doctorate degree from the University of Utrecht.

John de Kruif active positions

Companies	Position	Start
MERUS N.V.	Chief Tech/Sci/R&D Officer	2007-03-31

All active positions of John de Kruif

Former positions of John de Kruif

Companies	Position	End
Crucell NV Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands.	Corporate Officer/Principal	2006-09-30

See the detail of John de Kruif's experience

Training of John de Kruif

University of Utrecht

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of John de Kruif's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
MERUS N.V.	Health Technology

Private companies	1
Crucell NV Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands.	Health Technology